Arca
Skip to content
Tools
Tools

Colitis

Drug research and approvals for colitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 298 studies of colitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 161 drug trials for it since 2013, FDA has 6 approved and 17 open orphan designations naming it, and the EU has 5 authorised medicines for it.

  • Recruiting worldwide: 298
  • Trials authorized in Canada: 161
  • FDA orphan approvals: 6
  • EU medicines: 5

Recruiting now

Newest start dates first, of 298 recruiting on ClinicalTrials.gov ↗

Drug pipeline

2 in phase 3, 6 in phase 2, 1 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition
Infliximab
Phase 3 TNF-alpha inhibitor
Ustekinumab
Phase 3 Interleukin-12 inhibitor
Tacrolimus anhydrous
Phase 2 FK506-binding protein 1A inhibitor
Tofacitinib
Phase 2 Janus Kinase (JAK) inhibitor
Adalimumab
Phase 2 TNF-alpha inhibitor
Mesalamine
Phase 2 Arachidonate 5-lipoxygenase inhibitor
Mercaptopurine anhydrous
Phase 2 Amidophosphoribosyltransferase inhibitor
Vedolizumab
Phase 2 Integrin alpha-4/beta-7 inhibitor
CRS-3123
Phase 1 Methionine--tRNA ligase inhibitor

How its trials ended

1,292 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 368 whose ending is known, 40% met their primary endpoint, 7% missed it and 53% stopped early.

  • Completed, result not reported43334%
  • Ongoing32425%
  • Status unknown16713%
  • Met its primary endpoint14912%
  • Stopped: other or unclear836%
  • Stopped: enrollment or feasibility514%
  • Stopped: sponsor or business decision282%
  • Stopped: lack of efficacy262%
  • Missed its primary endpoint242%
  • Stopped: funding40%
  • Stopped: safety30%

Trials authorized in Canada

The 10 newest of 161; search them all in Canada trials
Oct 1, 2026A randomized trial of RIPK2 inhibitor OD-001 in combination with vedolizumab for moderately to severely active ulcerative colitisOD-001 (OD-07656) / VedolizumabOdyssey TherapeuticsPending
Sep 17, 2026A phase 2, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy, safety, pharmacokinetics, and…PALI-2108Palisade Bio, Inc.Pending
Aug 25, 2026A phase 2 platform basket study evaluating advanced therapies in subjects with moderately to severely active Crohn's disease or ulcerative colitisRisankizumab (ABBV-066) / Trosunilimab / ABBV-701AbbVieOngoing
Aug 12, 2026A phase III, multicenter, double-blind, placebo-controlled study to assess the efficacy and safety of induction therapy with RO7790121 in patients with…RO7790121 (TL1A (RVT-3101))RochePending
May 20, 2026A phase 3 randomized, double-blind, and active-controlled, multicenter study to evaluate the efficacy and safety of JNJ-78934804 in participants with…JNJ-78934804 (guselkumab-golimumab) / GuselkumabJohnson & JohnsonOngoing
Apr 24, 2026A phase 2a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MK-8690 in adult participants with moderately to severely…MK-8690Merck & Co. (MSD)Ongoing
Apr 2, 2026Master protocol title: a master protocol for phase 2, randomized, controlled studies of multiple interventions for the treatment of adults with moderately to…Mirikizumab (LY3074828) / LY4395089Eli LillyOngoing
Mar 25, 2026A randomized, multicenter, double-blind, placebo-controlled development program to evaluate the efficacy and safety of LY4268989 (MORF-057) for the treatment…LY4268989 (MORF-057)Eli LillyOngoing
Feb 20, 2026A phase 2, multicenter, randomized, double-blind, active-controlled study of LY4268989 (MORF-057) co-administered with mirikizumab in adults with moderately to…LY4268989 (MORF-057) / Mirikizumab (LY3074828)Eli LillyOngoing
Feb 4, 2026A multi-centre, randomised controlled trial comparing fecal microbiota transplantation to placebo in an expanded ulcerative colitis population: a feasibility…Fecal microbiota for transplantation (FMT)The Governors of The University of AlbertaPending

FDA orphan designations

Approved first, then open designations, newest first; 15 of 23
Aug 28, 2026StelaraTreatment of adults and pediatric patients 2 years of age and older with moderately to severely active ulcerative colitisJanssen Biotech, Inc.Approved
Oct 7, 2025SimponiTreatment of adults and pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitisJanssen Biotech, Inc.Approved
Feb 24, 2021HumiraTreatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. Limitations of Use: The…AbbVie, Inc.Approved
Jun 26, 2020LialdaLialda (mesalamine) is indicated for the treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at…Takeda Development Center Americas, Inc.Approved
Sep 23, 2011RemicadeFor reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with…Janssen Biotech, Inc.Approved
Dec 20, 2006ColazalTreatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal…Salix Pharmaceuticals, Inc.Approved
Aug 9, 2021Mixture of delta 9-tetrahydrocannabinol glycosidesTreatment of pediatric ulcerative colitis between the ages of 0-18 yearsVitality Biopharma, Inc.Designated
Mar 30, 2020Magnesium lysinate bis Resolvin E1Treatment of pediatric ulcerative colitisThetis PharmaceuticalsDesignated
Dec 30, 2019UpadacitinibTreatment of pediatric ulcerative colitisAbbVieDesignated
Jan 17, 2018ApremilastTreatment of pediatric patients with ulcerative colitisAmgen Inc.Designated
Nov 16, 2017Cholera toxin B subunitTreatment of ulcerative colitis in pediatric patientsAliment Wellness LLCDesignated
Aug 31, 20175-(4-carboxymethyl-phenylazo)-2-hydroxybenzoic acid…Treatment of pediatric ulcerative colitis (UC)9 Meters Biopharma, Inc.Designated
Jun 27, 2017Hydrocortisone acetateTreatment of pediatric ulcerative colitisCristcot HCA, LLCDesignated
Jun 15, 2017Humanized immunoglobulin G4-variant monoclonal antibody…Treatment of ulcerative colitis in pediatric patientsEli Lilly & CompanyDesignated
Dec 29, 2015OzanimodTreatment of pediatric (0 through 16 years of age) ulcerative colitisCelgene CorporationDesignated

Medicines authorised in the EU

Newest first
Feb 16, 2024VelsipityEtrasimodPfizer Europe MA EEIGEMA ↗
May 26, 2023OmvohMirikizumabEli Lilly Nederland B.V.EMA ↗
May 20, 2020ZeposiaOzanimodBristol-Myers Squibb Pharma EEIGEMA ↗
May 18, 2018ZesslyInfliximab · biosimilarSandoz GmbHEMA ↗
May 22, 2014EntyvioVedolizumabTakeda Pharma A/SEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.